MYO

Business Context and Reporting Period

Company: MYOMO, INC. (MYO)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: Myomo is a wearable medical robotics company developing myoelectric orthotics (MyoPro) for patients with neuromuscular disorders. The company operates as a single segment, selling directly to patients (direct billing) and to Orthotics and Prosthetics (O&P) providers, the Veterans Administration, and international distributors.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 10% quarter-over-quarter (QoQ) and 44% year-over-year (YoY) for the nine-month period, driven by higher unit deliveries to Medicare Part B patients and O&P practices.
• Gross Margin Compression: Gross margin declined to 63.8% (Q3 2025) from 75.4% (Q3 2024). The decrease is attributed to higher material costs, increased manufacturing overhead (including a new headquarters), and unfavorable timing of supplemental insurance payments compared to the prior year.
• Operating Expenses: Total operating expenses rose 26% QoQ and 50% YoY. Selling, clinical, and marketing expenses increased 54% QoQ due to higher advertising spend and clinical headcount. R&D expenses increased 22% QoQ due to engineering and product development investments.
• Debt Financing: The company utilized its revolving credit line and term loan facility, resulting in $4.0 million in outstanding debt as of September 30, 2025, compared to zero debt in the prior year-end period.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity and Capital Resources: Management believes current cash ($12.6 million) and recent financing will fund operations for at least the next 12 months. However, the company anticipates continuing net losses and negative operating cash flows throughout 2025.
• Subsequent Financing Event: On November 4, 2025, Myomo entered into a Loan and Security Agreement with Avenue Capital Management for up to $17.5 million. $12.5 million was funded at closing to repay existing Silicon Valley Bank debt and for general corporate purposes. The loan includes a warrant to purchase up to $1.31 million of stock.
• Reimbursement Risks: The company faces significant risk regarding Medicare Advantage plans, which have reduced authorizations since late 2024. Additionally, CMS billing contractors initiated pre-payment audits in two regions; while 31 of 39 audited claims were paid, the outcome of remaining appeals is uncertain.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to IT general controls (privileged access rights and user provisioning). Remediation efforts are underway but not yet fully tested.
• Advertising Challenges: Algorithm changes by social media advertising partners in early 2025 led to decreased lead generation and higher costs per pipeline addition, impacting revenue growth.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $13.4 million operating cash burn over nine months against the $12.6 million cash balance and the new $12.5 million loan tranche.
• Medicare Advantage Trends: Monitor the authorization rates and reimbursement trends for Medicare Advantage plans, which represented 18% of Q3 2025 revenue but have shown declining authorization rates.
• Debt Covenants: Review the financial covenants in the new Avenue Capital agreement, specifically the requirement to maintain $2.5 million in unrestricted cash and limits on trailing six-month cash burn.
• Remediation of Material Weakness: Confirm the timeline for testing and closing the material weakness in IT general controls to ensure future financial reporting reliability.
• Gross Margin Trajectory: Assess whether the 63.8% gross margin is a new baseline or if cost controls will restore margins closer to the 75% levels seen in 2024.